Adial Pharmaceuticals (ADIL) Price/OCF Ratio: History & Chart

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T12:50:20.187Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:50:20.187Z.

Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 11,422,621
TTM operating cash flow · period ending 2026-06-30: -11,132,939

FMP input reference: fa223cd5a0006a47bd3f11d3634c651a1c818c2f8beb58cb941cded2cdd6eca8

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

ADIL Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

ADIL Competitors' Price/OCF Ratio

ADIL

Adial Pharmaceuticals, Inc.

Current

Market Cap

$11.42M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BFRI

Biofrontera Inc.

vs ADIL

Market Cap

$11.41M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BFRG

Bullfrog AI Holdings, Inc. Common Stock

vs ADIL

Market Cap

$11.01M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GDTC

CytoMed Therapeutics Limited

vs ADIL

Market Cap

$11.95M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BIVI

BioVie Inc.

vs ADIL

Market Cap

$10.86M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNSY

Cerenome, Inc.

vs ADIL

Market Cap

$10.74M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTSO

Cytosorbents Corporation

vs ADIL

Market Cap

$12.46M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CABR

Caring Brands, Inc.

vs ADIL

Market Cap

$10.27M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DARE

Dare Bioscience, Inc.

vs ADIL

Market Cap

$12.63M

Price/OCF Ratio

N/A

TTM Avg

3.83

3Y Avg

3.83

5Y Avg

3.83

ICU

SeaStar Medical Holding Corporation

vs ADIL

Market Cap

$10.07M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Adial Pharmaceuticals, Inc. (ADIL)	$11.42M	N/A	N/A	N/A	N/A
Biofrontera Inc. (BFRI)vs ›	$11.41M	N/A	N/A	N/A	N/A
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$11.01M	N/A	N/A	N/A	N/A
CytoMed Therapeutics Limited (GDTC)vs ›	$11.95M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$10.86M	N/A	N/A	N/A	N/A
Cerenome, Inc. (CNSY)vs ›	$10.74M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$12.46M	N/A	N/A	N/A	N/A
Caring Brands, Inc. (CABR)vs ›	$10.27M	N/A	N/A	N/A	N/A
Dare Bioscience, Inc. (DARE)vs ›	$12.63M	N/A	3.83	3.83	3.83
SeaStar Medical Holding Corporation (ICU)vs ›	$10.07M	N/A	N/A	N/A	N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

ADIL Price/OCF Ratio Metrics

ADIL Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics